Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer

References

• GLOBOCAN v1.2 Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 2008
   Google Scholar
• Siegel R Naishadham D Jemal A Cancer statistics, 2012 CA Cancer J Clin 2012 62 1 10 29 22237781
   PubMed Web of Science ®Google Scholar
• Semenas J Allegrucci C Boorjian SA Mongan NP Persson JL Overcoming drug resistance and treating advanced prostate cancer Curr Drug Targets 2012 13 10 1308 1323 22746994
   PubMed Web of Science ®Google Scholar
• Huggins C Hodges CV Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941 J Urol 2002 167 2 Pt 2 948 951 discussion 952 11905923
   PubMed Web of Science ®Google Scholar
• Huggins C The hormone-dependent cancers JAMA 1963 186 481 483 14053350
   PubMed Web of Science ®Google Scholar
• Perlmutter MA Lepor H Androgen deprivation therapy in the treatment of advanced prostate cancer Rev Urol 2007 9 Suppl 1 S3 S8 17387371
   PubMedGoogle Scholar
• Harris WP Mostaghel EA Nelson PS Montgomery B Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion Nat Clin Pract Urol 2009 6 2 76 85 19198621
   PubMedGoogle Scholar
• National Cancer Institute [homepage on the Internet] Prostate cancer National Institutes of Health 2012 Available from: http://cancer.gov/cancertopics/wyntk/prostate Accessed June 5, 2013
   Google Scholar
• Crawford ED Eisenberger MA McLeod DG A controlled trial of leuprolide with and without flutamide in prostatic carcinoma N Engl J Med 1989 321 7 419 424 2503724
   PubMed Web of Science ®Google Scholar
• Eisenberger MA Blumenstein BA Crawford ED Bilateral orchiectomy with or without flutamide for metastatic prostate cancer N Engl J Med 1998 339 15 1036 1042 9761805
   PubMed Web of Science ®Google Scholar
• Crawford ED Combined androgen blockade Urology 1989 34 4 Suppl 22 26 discussion 46–56 2508291
   PubMed Web of Science ®Google Scholar
• The Leuprolide Study Group Leuprolide versus diethylstilbestrol for metastatic prostate cancer N Engl J Med 1984 311 20 1281 1286 6436700
   PubMed Web of Science ®Google Scholar
• Walsh PC Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. The Medical Research Council Prostate Cancer Working Party Investigators Group J Urol 1997 158 4 1623 1624 9302187
   PubMedGoogle Scholar
• Messing EM Manola J Sarosdy M Wilding G Crawford ED Trump D Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer N Engl J Med 1999 341 24 1781 1788 10588962
   PubMed Web of Science ®Google Scholar
• Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists’ Collaborative Group Lancet 2000 355 9214 1491 1498 10801170
   PubMed Web of Science ®Google Scholar
• Sharma SV Haber DA Settleman J Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents Nat Rev Cancer 2010 10 4 241 253 20300105
   PubMed Web of Science ®Google Scholar
• Holzbeierlein J Lal P LaTulippe E Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance Am J Pathol 2004 164 1 217 227 14695335
   PubMed Web of Science ®Google Scholar
• Shah RB Mehra R Chinnaiyan AM Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program Cancer Res 2004 64 24 9209 9216 15604294
   PubMed Web of Science ®Google Scholar
• Tamura K Furihata M Tsunoda T Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles Cancer Res 2007 67 11 5117 5125 17545589
   PubMed Web of Science ®Google Scholar
• Koivisto P Kononen J Palmberg C Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer Cancer Res 1997 57 2 314 319 9000575
   PubMed Web of Science ®Google Scholar
• Chen CD Welsbie DS Tran C Molecular determinants of resistance to antiandrogen therapy Nat Med 2004 10 1 33 39 14702632
   PubMed Web of Science ®Google Scholar
• Stanbrough M Bubley GJ Ross K Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer Cancer Res 2006 66 5 2815 2825 16510604
   PubMed Web of Science ®Google Scholar
• Montgomery RB Mostaghel EA Vessella R Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth Cancer Res 2008 68 11 4447 4454 18519708
   PubMed Web of Science ®Google Scholar
• Seruga B Ocana A Tannock IF Drug resistance in metastatic castration-resistant prostate cancer Nat Rev Clin Oncol 2011 8 1 12 23 20859283
   PubMed Web of Science ®Google Scholar
• Yeh S Miyamoto H Shima H Chang C From estrogen to androgen receptor: a new pathway for sex hormones in prostate Proc Natl Acad Sci U S A 1998 95 10 5527 5532 9576916
   PubMed Web of Science ®Google Scholar
• Yeh S Kang HY Miyamoto H Differential induction of androgen receptor transactivation by different androgen receptor coactivators in human prostate cancer DU145 cells Endocrine 1999 11 2 195 202 10709768
   PubMed Web of Science ®Google Scholar
• Gregory CW He B Johnson RT A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy Cancer Res 2001 61 11 4315 4319 11389051
   PubMed Web of Science ®Google Scholar
• Tran C Ouk S Clegg NJ Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 2009 324 5928 787 790 19359544
   PubMed Web of Science ®Google Scholar
• Wang Q Li W Zhang Y Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer Cell 2009 138 2 245 256 19632176
   PubMed Web of Science ®Google Scholar
• Clegg NJ Wongvipat J Joseph JD ARN-509: a novel antiandrogen for prostate cancer treatment Cancer Res 2012 72 6 1494 1503 22266222
   PubMed Web of Science ®Google Scholar
• Scher HI Sawyers CL Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis J Clin Oncol 2005 23 32 8253 8261 16278481
   PubMed Web of Science ®Google Scholar
• Petrylak DP Tangen CM Hussain MH Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 2004 351 15 1513 1520 15470214
   PubMed Web of Science ®Google Scholar
• Tannock IF de Wit R Berry WR Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 2004 351 15 1502 1512 15470213
   PubMed Web of Science ®Google Scholar
• de Bono JS Oudard S Ozguroglu M Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 2010 376 9747 1147 1154 20888992
   PubMed Web of Science ®Google Scholar
• Berthold DR Pond GR Soban F de Wit R Eisenberger M Tannock IF Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study J Clin Oncol 2008 26 2 242 245 18182665
   PubMed Web of Science ®Google Scholar
• Darshan MS Loftus MS Thadani-Mulero M Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer Cancer Res 2011 71 18 6019 6029 21799031
   PubMed Web of Science ®Google Scholar
• Gottesman MM Fojo T Bates SE Multidrug resistance in cancer: role of ATP-dependent transporters Nat Rev Cancer 2002 2 1 48 58 11902585
   PubMed Web of Science ®Google Scholar
• Berrieman HK Lind MJ Cawkwell L Do beta-tubulin mutations have a role in resistance to chemotherapy? Lancet Oncol 2004 5 3 158 164 15003198
   PubMed Web of Science ®Google Scholar
• Bhalla KN Microtubule-targeted anticancer agents and apoptosis Oncogene 2003 22 56 9075 9086 14663486
   PubMed Web of Science ®Google Scholar
• Metzger E Wissmann M Yin N LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription Nature 2005 437 7057 436 439 16079795
   PubMed Web of Science ®Google Scholar
• Kahl P Gullotti L Heukamp LC Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence Cancer Res 2006 66 23 11341 11347 17145880
   PubMed Web of Science ®Google Scholar
• Culig Z Hoffmann J Erdel M Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system Br J Cancer 1999 81 2 242 251 10496349
   PubMed Web of Science ®Google Scholar
• Nguyen TV Yao M Pike CJ Flutamide and cyproterone acetate exert agonist effects: induction of androgen receptor-dependent neuroprotection Endocrinology 2007 148 6 2936 2943 17347309
   PubMed Web of Science ®Google Scholar
• Medivation Medivation’s MDV3100 shown to be effective in a pre-clinical model of hormone-refractory prostate cancer [press release] San Francisco, CA Medivation 2007 2 26 Available from: http://investors.medivation.com/releasedetail.cfm?ReleaseID=231214 Accessed June 5, 2013
   Google Scholar
• Massard C Fizazi K Targeting continued androgen receptor signaling in prostate cancer Clin Cancer Res 2011 17 12 3876 3883 21680543
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration Enzalutamide (XTANDI capsules) Silver Spring, MD US Food and Drug Administration 2012 Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm317997.htm Accessed June 5, 2013
   Google Scholar
• XTANDI [prescribing information] Northbrook, IL Astellas Pharma US, Inc 2012
   Google Scholar
• ClinicalTrials.gov Available from: http://www.clinicaltrials.gov/ct2/home Accessed 1 July, 2013
   Google Scholar
• Scher HI Beer TM Higano CS Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study Lancet 2010 375 9724 1437 1446 20398925
   PubMed Web of Science ®Google Scholar
• Scher HI Beer TM Higano CS Phase I-II study of MDV3100 in castration-resistant prostate cancer (CRPC) J Clin Oncol 2009 27 abstract 151
   Google Scholar
• ClinicalTrials Current clinical trials for MDV3100 2012 http://www.clinicaltrials.gov/ct2/results?term=MDV3100&recr=&rslt=&type=Intr&cond=&intr=&outc=&spons=Astellas&lead=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&phase=0&phase=1&phase=2&phase=3&rcv_s=&rcv_e=&lup_s=&lup_e=Accessed March 14, 2012
   Google Scholar
• Scher HI Fizazi K Saad F Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 2012 367 13 1187 1197 22894553
   PubMed Web of Science ®Google Scholar
• de Bono JS Logothetis CJ Molina A Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 2011 364 21 1995 2005 21612468
   PubMed Web of Science ®Google Scholar
• Li Y Chan SC Brand LJ Hwang TH Silverstein KA Dehm SM Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines Cancer Res 2013 73 2 483 489 23117885
   PubMed Web of Science ®Google Scholar
• Kantoff PW Higano CS Shore ND Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 2010 363 5 411 422 20818862
   PubMed Web of Science ®Google Scholar